Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 6/2014

01-12-2014 | Correspondence

No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan

Authors: D. Focosi, L. Macera, E. Ciabatti, S. Galimberti, M. Petrini, A. M. Carella, M. Pistello, L. Ceccherini-Nelli, F. Maggi

Published in: Infection | Issue 6/2014

Login to get access

Excerpt

Dear Sirs, …
Literature
1.
Tuccori M, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15:1214–9.PubMedCentralPubMedCrossRef
2.
3.
4.
Focosi D, et al. The role of bone marrow cells for JCV pathogenicity. J Clin Virol. 2009;45:230–1.PubMedCrossRef
5.
Ibatici A, et al. Safety and efficacy of yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol. 2014;164:710–6.PubMedCrossRef
Metadata
Title
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan
Authors
D. Focosi
L. Macera
E. Ciabatti
S. Galimberti
M. Petrini
A. M. Carella
M. Pistello
L. Ceccherini-Nelli
F. Maggi
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0677-2

Other articles of this Issue 6/2014

Infection 6/2014 Go to the issue

Review

Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies

Original Paper

Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients

Original Paper

Risk factors for linezolid-associated thrombocytopenia in adult patients

Case Report

Fatal Strongyloides hyper-infection in a patient with myasthenia gravis

Images in Infection

Oral manifestation of lepromatous leprosy: diagnosis and management

Case Report

Klebsiella pneumoniae pharyngitis mimicking malignancy: a diagnostic dilemma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits